title: Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study.
abstract: BACKGROUND
  Stent thrombosis is an infrequent complication of intracoronary stenting that often has devastating clinical consequences. This study assesses the additional benefit of heparin coating with the BX VELOCITY Balloon-Expandable Stent with HEPACOAT, Carmeda end-point attached heparin (HEPACOAT) in patients with de novo or restenotic native coronary artery lesions treated with aspirin monotherapy after optimal stenting.
  
  
  RESULTS
  This was a multicenter, prospective, nonrandomized, pilot study. Two hundred patients (69% men; mean age, 64.1+/-11.2 years) meeting the eligibility criteria were treated with the HEPACOAT stent and aspirin alone after stenting. Any other antiplatelet or anticoagulation therapy was not permitted. Procedural success was achieved in all patients. There were 3 postprocedural non-Q-wave myocardial infarctions. The primary end point of stent thrombosis at 30 days occurred in 2 of 200 patients (1%): in one after blunt chest trauma and in the other in the setting of essential thrombocytosis. Major adverse cardiac events (death, myocardial infarction, target lesion revascularization, and coronary artery bypass grafting) were observed at 30 days in 5 of 200 (2.5%) patients.
  
  
  CONCLUSIONS
  The BX VELOCITY stent with HEPACOAT and aspirin alone after the procedure was safe in select patients with de novo or restenotic lesions in native coronary arteries. Heparin coating provides additional protection against stent thrombosis.
authors.affiliation: Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York, NY 10021, USA. rmehran@crf.org
authors.forename: Roxana
authors.initials: R
authors.lastname: Mehran
authors.forename: Eve D
authors.initials: ED
authors.lastname: Aymong
authors.forename: Dale T
authors.initials: DT
authors.lastname: Ashby
authors.forename: Tim
authors.initials: T
authors.lastname: Fischell
authors.forename: Hall
authors.initials: H
authors.lastname: Whitworth
authors.forename: Robert
authors.initials: R
authors.lastname: Siegel
authors.forename: William
authors.initials: W
authors.lastname: Thomas
authors.forename: S Chiu
authors.initials: SC
authors.lastname: Wong
authors.forename: Raj
authors.initials: R
authors.lastname: Narasimaiah
authors.forename: Alexandra J
authors.initials: AJ
authors.lastname: Lansky
authors.forename: Martin B
authors.initials: MB
authors.lastname: Leon
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D003328:Coronary Thrombosis / Q000517:prevention & control*; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D015607:Stents / Q000009:adverse effects
chemical_list: D005343:Fibrinolytic Agents; D006493:Heparin; D001241:Aspirin